Melatonin is routinely sold as a sedative, yet pharmacologically it behaves nothing like a benzodiazepine or antihistamine. It binds two distinct G-protein-coupled receptors — MT1 and MT2 — that signal through different downstream cascades, govern different aspects of sleep and circadian biology, and are expressed not just in the suprachiasmatic nucleus (SCN) but throughout mitochondria, retina, vasculature, and immune tissue. Treating melatonin as a hypnotic obscures what it actually is: the body’s chemical encoding of darkness, and one of the most evolutionarily conserved antioxidants on the planet.
What Is Melatonin?
Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine synthesized from tryptophan via serotonin, primarily in the pineal gland but also in the retina, gut, bone marrow, and — critically — within mitochondria themselves. Pineal secretion is gated by the SCN, which receives light input from intrinsically photosensitive retinal ganglion cells. Plasma melatonin rises 2–3 hours before habitual sleep onset (the dim-light melatonin onset, or DLMO), peaks between 2:00 and 4:00 AM, and falls to near-zero during daylight.[1]
The hormone’s biological actions are mediated by two high-affinity receptors: MT1 (MTNR1A) and MT2 (MTNR1B), both class A GPCRs. A third binding site, MT3, is now identified as the cytosolic enzyme quinone reductase 2 and is not a true receptor. Understanding the divergent roles of MT1 and MT2 is essential to using melatonin rationally.[2]
How MT1 and MT2 Receptor Signaling Works
MT1 Signaling — Sleep Onset and SCN Inhibition: MT1 receptors are densely expressed in the SCN and couple primarily to Gi/o proteins, inhibiting adenylyl cyclase and reducing intracellular cAMP. Activation of MT1 in the SCN acutely suppresses the neuronal firing rate that maintains wakefulness — this is the mechanism behind melatonin’s mild sleep-promoting effect. MT1 also modulates potassium channels and is the dominant receptor for melatonin’s effect on REM sleep promotion.[2]
MT2 Signaling — Circadian Phase Shifting: MT2 receptors mediate the phase-shifting (chronobiotic) effects of melatonin. Activation of MT2 in the SCN at the appropriate circadian time advances or delays the master clock, depending on the phase of administration. MT2 also appears more relevant to non-REM sleep depth and to the suppression of dopaminergic firing in the substantia nigra. The selective MT2 agonist IIK7 produces phase shifts without the acute sedation seen with non-selective agonists.[3]
SCN–Pineal Feedback Loop: The SCN drives pineal melatonin synthesis via a multi-synaptic pathway through the paraventricular nucleus and superior cervical ganglion. Circulating melatonin in turn feeds back onto SCN MT1 and MT2 receptors, reinforcing the day–night signal. This closed loop is why exogenous melatonin given at the wrong circadian phase can disrupt rather than entrain rhythms — a common clinical error.[1]
Mitochondrial Melatonin: Mitochondria synthesize melatonin locally and express MT1 receptors on the outer mitochondrial membrane. Intramitochondrial melatonin scavenges reactive oxygen species directly — without requiring receptor binding — and also signals through mitochondrial MT1 to stabilize complex I activity and reduce cytochrome c release. Concentrations within mitochondria are estimated to be orders of magnitude higher than in plasma.[4]
Clinical Evidence
Circadian Realignment: Low-dose melatonin (0.3–0.5 mg) administered 4–6 hours before DLMO produces reliable phase advances in delayed sleep-wake phase disorder, shift workers, and transmeridian travelers. Higher pharmacologic doses (3–10 mg) do not increase phase-shifting magnitude and may blunt it by saturating MT2 receptors and producing daytime carryover.[3]
Sleep Architecture: A meta-analysis of randomized trials found that exogenous melatonin reduces sleep onset latency by approximately 7 minutes and increases total sleep time by approximately 8 minutes — modest effects compared with hypnotics. However, melatonin uniquely preserves and may enhance slow-wave sleep and REM sleep proportions, unlike GABAergic sedatives that suppress them.[5]
Mitochondrial and Neuroprotective Effects: Preclinical and translational work demonstrates that melatonin reduces oxidative damage in ischemia-reperfusion injury, sepsis, and neurodegeneration. Mechanisms include direct ROS scavenging, upregulation of glutathione peroxidase and superoxide dismutase, and stabilization of mitochondrial membrane potential. These actions explain why melatonin’s effective dose range for tissue protection (often 10–50 mg) is far higher than its chronobiotic dose.[4]
Age-Related Decline: Pineal melatonin output declines substantially with age, with nocturnal peaks in adults over 70 often less than one-third of young adult values. This decline correlates with fragmented sleep, reduced slow-wave sleep, and impaired circadian amplitude — and is one rationale for low-dose replacement in older adults.[1]
Safety Profile
Melatonin has a remarkably wide therapeutic index. Acute toxicity has not been reported even at gram-level doses. The most common adverse effects are next-day grogginess (more frequent with doses above 1 mg), vivid dreams, headache, and transient hypothermia. Because MT1 and MT2 are expressed on vascular smooth muscle, melatonin can produce mild blood pressure reduction — clinically useful in non-dipping hypertensives but worth noting in patients on antihypertensive polypharmacy.[2]
Dose-response is paradoxical: higher doses are not more effective for sleep and may worsen outcomes by desensitizing receptors and producing supraphysiologic plasma levels that persist into the biological day. Commercial supplements frequently contain 3–10 mg per tablet — roughly 10–30× the dose needed to achieve physiologic peak concentrations. For chronobiotic use, sub-milligram dosing is preferred. For antioxidant or adjunctive neuroprotective use, higher doses may be appropriate but should be timed to the biological night.
Drug interactions of note include CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) which can raise melatonin levels 5–17 fold, and beta-blockers, which suppress endogenous melatonin by blocking pineal beta-1 receptors.
Melatonin vs Other Sleep and Circadian Approaches
Versus GABAergic Hypnotics: Benzodiazepines and Z-drugs (zolpidem, eszopiclone) act on GABA-A receptors to produce sedation but suppress slow-wave and REM sleep, carry dependence risk, and do not phase-shift the circadian clock. Melatonin does the opposite: weak sedation, preserved architecture, and genuine chronobiotic action.[5]
Versus Ramelteon and Tasimelteon: Ramelteon is a non-selective MT1/MT2 agonist approved for sleep onset insomnia; tasimelteon is approved for non-24-hour sleep-wake disorder. Both have higher receptor affinity than melatonin and longer half-lives, but lack melatonin’s direct antioxidant action and broader tissue distribution. They are pharmaceutical analogs of one facet of melatonin’s biology.[3]
Versus Light Therapy: Bright light in the morning and darkness in the evening remain the most potent circadian zeitgebers. Melatonin is best understood as complementary — chemical darkness layered onto behavioral light hygiene, not a substitute for it.
References
- Arendt J. “Melatonin and human rhythms.” Chronobiology International. 2006;23(1-2):21-37.
- Dubocovich ML, et al. “International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.” Pharmacological Reviews. 2010;62(3):343-380.
- Liu J, et al. “MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.” Annual Review of Pharmacology and Toxicology. 2016;56:361-383.
- Reiter RJ, et al. “Melatonin as an antioxidant: under promises but over delivers.” Journal of Pineal Research. 2016;61(3):253-278.
- Ferracioli-Oda E, et al. “Meta-analysis: melatonin for the treatment of primary sleep disorders.” PLoS One. 2013;8(5):e63773.
